INmune Bio Inc. (NASDAQ: INMB) and Anthony Nolan announced an expanded collaboration agreement to advance the CORDStrom mesenchymal stromal cell platform for treating recessive dystrophic epidermolysis bullosa, oncology and inflammatory diseases.

The amended Material Transfer and License Agreement, effective April 29, 2026, extends the partnership between the clinical-stage biotechnology company and the UK-based stem cell charity. The collaboration secures long-term provision of umbilical cord tissue to support INmune Bio's cellular therapy development programs.

CORDStrom utilizes umbilical cord-derived mesenchymal stromal cells that are tested, screened and pooled to create standardized cell banks. The platform addresses consistency challenges in MSC therapies by establishing rigorous materials acceptance criteria, including neonatal weight and maternal age specifications.

The collaboration targets several therapeutic areas including CORDStrom for recessive dystrophic epidermolysis bullosa, CORDStrom-col7a for systemic EB treatment, CORDStrom-TRAIL for solid tumors, and applications in osteoarthritis and systemic lupus erythematosus.

"We view CORDStrom as a tremendous platform that finally solves the fundamental challenge of understanding MSCs as a drug," said David Moss, CEO of INmune Bio. "By partnering with Anthony Nolan's Cell Therapy & Laboratory Services, we are combining the most advanced MSC cell platform with the most reliable source of cellular starting material."

The agreement includes provisions for traceability and quality management in accordance with Good Manufacturing Practice and Human Tissue Authority standards as INmune Bio prepares for potential commercial approval.

Anthony Nolan operates a stem cell register and develops cell therapy treatments. The charity's Cell Therapy and Laboratory Services division provides ethically sourced starting materials for research and clinical applications.